227 related articles for article (PubMed ID: 25967746)
41. [Dysregulation of HGF/c-Met signal pathway and their targeting drugs in lung cancer].
Li Y; Liu H; Chen J
Zhongguo Fei Ai Za Zhi; 2014 Aug; 17(8):625-34. PubMed ID: 25130970
[TBL] [Abstract][Full Text] [Related]
42. Frequent hepatocyte growth factor overexpression and low frequency of c-Met gene amplification in human papillomavirus-negative tonsillar squamous cell carcinoma and their prognostic significances.
Kwon MJ; Kim DH; Park HR; Shin HS; Kwon JH; Lee DJ; Kim JH; Cho SJ; Nam ES
Hum Pathol; 2014 Jul; 45(7):1327-38. PubMed ID: 24810547
[TBL] [Abstract][Full Text] [Related]
43. Interaction between human-breast cancer metastasis and bone microenvironment through activated hepatocyte growth factor/Met and beta-catenin/Wnt pathways.
Previdi S; Maroni P; Matteucci E; Broggini M; Bendinelli P; Desiderio MA
Eur J Cancer; 2010 Jun; 46(9):1679-91. PubMed ID: 20350802
[TBL] [Abstract][Full Text] [Related]
44. HGF/MET signaling in ovarian cancer.
Zhou HY; Pon YL; Wong AS
Curr Mol Med; 2008 Sep; 8(6):469-80. PubMed ID: 18781954
[TBL] [Abstract][Full Text] [Related]
45. HGF/MET signaling promotes glioma growth via up-regulation of Cox-2 expression and PGE2 production.
Zhao Y; Sun Y; Zhang H; Liu X; Du W; Li Y; Zhang J; Chen L; Jiang C
Int J Clin Exp Pathol; 2015; 8(4):3719-26. PubMed ID: 26097553
[TBL] [Abstract][Full Text] [Related]
46. Targeting the c-Met pathway potentiates glioblastoma responses to gamma-radiation.
Lal B; Xia S; Abounader R; Laterra J
Clin Cancer Res; 2005 Jun; 11(12):4479-86. PubMed ID: 15958633
[TBL] [Abstract][Full Text] [Related]
47. Mechanisms of hepatocyte growth factor-induced retinal endothelial cell migration and growth.
Cai W; Rook SL; Jiang ZY; Takahara N; Aiello LP
Invest Ophthalmol Vis Sci; 2000 Jun; 41(7):1885-93. PubMed ID: 10845613
[TBL] [Abstract][Full Text] [Related]
48. Tumor-stromal cell interaction under hypoxia increases the invasiveness of pancreatic cancer cells through the hepatocyte growth factor/c-Met pathway.
Ide T; Kitajima Y; Miyoshi A; Ohtsuka T; Mitsuno M; Ohtaka K; Koga Y; Miyazaki K
Int J Cancer; 2006 Dec; 119(12):2750-9. PubMed ID: 16998831
[TBL] [Abstract][Full Text] [Related]
49. Expression of the HGF receptor c-met by macrophages in experimental autoimmune encephalomyelitis.
Moransard M; Sawitzky M; Fontana A; Suter T
Glia; 2010 Apr; 58(5):559-71. PubMed ID: 19941340
[TBL] [Abstract][Full Text] [Related]
50. The HGF/MET pathway as target for the treatment of multiple myeloma and B-cell lymphomas.
Mahtouk K; Tjin EP; Spaargaren M; Pals ST
Biochim Biophys Acta; 2010 Dec; 1806(2):208-19. PubMed ID: 20655987
[TBL] [Abstract][Full Text] [Related]
51. Targeting the Hepatocyte Growth Factor and c-Met Signaling Axis in Bone Metastases.
Whang YM; Jung SP; Kim MK; Chang IH; Park SI
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30658428
[TBL] [Abstract][Full Text] [Related]
52. HGF/MET pathway aberrations as diagnostic, prognostic, and predictive biomarkers in human cancers.
Moosavi F; Giovannetti E; Saso L; Firuzi O
Crit Rev Clin Lab Sci; 2019 Dec; 56(8):533-566. PubMed ID: 31512514
[TBL] [Abstract][Full Text] [Related]
53. Molecular genetic analysis of the hepatocyte growth factor/MET signaling pathway in pediatric medulloblastoma.
Onvani S; Terakawa Y; Smith C; Northcott P; Taylor M; Rutka J
Genes Chromosomes Cancer; 2012 Jul; 51(7):675-88. PubMed ID: 22447520
[TBL] [Abstract][Full Text] [Related]
54. Radiation stimulates HGF receptor/c-Met expression that leads to amplifying cellular response to HGF stimulation via upregulated receptor tyrosine phosphorylation and MAP kinase activity in pancreatic cancer cells.
Qian LW; Mizumoto K; Inadome N; Nagai E; Sato N; Matsumoto K; Nakamura T; Tanaka M
Int J Cancer; 2003 May; 104(5):542-9. PubMed ID: 12594808
[TBL] [Abstract][Full Text] [Related]
55. NK4, an antagonist of hepatocyte growth factor (HGF), inhibits growth of multiple myeloma cells: molecular targeting of angiogenic growth factor.
Du W; Hattori Y; Yamada T; Matsumoto K; Nakamura T; Sagawa M; Otsuki T; Niikura T; Nukiwa T; Ikeda Y
Blood; 2007 Apr; 109(7):3042-9. PubMed ID: 17179234
[TBL] [Abstract][Full Text] [Related]
56. Molecular mechanism(s) of regulation(s) of c-MET/HGF signaling in head and neck cancer.
Raj S; Kesari KK; Kumar A; Rathi B; Sharma A; Gupta PK; Jha SK; Jha NK; Slama P; Roychoudhury S; Kumar D
Mol Cancer; 2022 Jan; 21(1):31. PubMed ID: 35081970
[TBL] [Abstract][Full Text] [Related]
57. Expression of hepatocyte growth factor and the proto-oncogenic receptor c-Met in canine osteosarcoma.
Fieten H; Spee B; Ijzer J; Kik MJ; Penning LC; Kirpensteijn J
Vet Pathol; 2009 Sep; 46(5):869-77. PubMed ID: 19429984
[TBL] [Abstract][Full Text] [Related]
58. Targeting c-met receptor tyrosine kinase by the DNA aptamer SL1 as a potential novel therapeutic option for myeloma.
Zhang Y; Gao H; Zhou W; Sun S; Zeng Y; Zhang H; Liang L; Xiao X; Song J; Ye M; Yang Y; Zhao J; Wang Z; Liu J
J Cell Mol Med; 2018 Dec; 22(12):5978-5990. PubMed ID: 30353654
[TBL] [Abstract][Full Text] [Related]
59. C-Met as a potential target for the treatment of gastrointestinal cancer: Current status and future perspectives.
Bahrami A; Shahidsales S; Khazaei M; Ghayour-Mobarhan M; Maftouh M; Hassanian SM; Avan A
J Cell Physiol; 2017 Oct; 232(10):2657-2673. PubMed ID: 28075018
[TBL] [Abstract][Full Text] [Related]
60. HGF/MET-directed therapeutics in gastroesophageal cancer: a review of clinical and biomarker development.
Hack SP; Bruey JM; Koeppen H
Oncotarget; 2014 May; 5(10):2866-80. PubMed ID: 24930887
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
